Your SlideShare is downloading. ×
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
The Pain Management Market Outlook To 2014: Competitive ...
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

The Pain Management Market Outlook To 2014: Competitive ...

5,944

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
5,944
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
207
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. For a clearer market perspective The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Report Price £1995/ 2880/$3835 Publication date June 2009 H E A LT H C A R E
  • 2. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities About Us Business Insights' portfolio of healthcare reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. Business Insights’ reports are authored by independent experts and contain findings from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight. Report Overview The global pain management market continued to demonstrate strong Pages 216 growth in 2007, despite patent expiries of leading products and strong generic competition. The NSAIDs segment of the market has overcome Figures 13 the impact of an FDA-imposed black box warning in 2005, however the local anesthetics market is facing significant generic penetration as the Tables 81 FDA has relaxed the requirements for the approval of the generic Lidoderm. “Use this report to assess ‘The Pain Management Market Outlook to 2014’ is a new report leading brands of treatment published by Business Insights that provides comprehensive coverage of for each indication based on major markets within the global pain management area, incorporating a H1 2008 sales and compare the outlooks of leading epidemiological analysis of key neuropathic and nociceptive pain companies within the pain indications and the main factors impacting their prevalence. Current management market...” leading brands of treatment within each indication are analysed with sales data from H1 2008 and the top ten leading players of the market are examined in detail. This report reviews the factors and underlying trends that are shaping the pain management market and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2009-14 period are also provided.
  • 3. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Key Findings The global pain management market generated $46.4bn sales in 2007, a 12.5% increase over 2006. The most prevalent forms of neuropathic pain in the seven major markets were neuralgia/fibromyalgia and lower back pain, with 16.3m and 15.9m cases respectively during 2008. Analgesics (narcotics and non–narcotics) account for 43% of the global pain management market, having generated revenues of $19.9bn in 2007. The segment also demonstrated robust 15.2% growth y–o–y. Table 2.4: Estimated prevalence of Narcotics segment is dominated by Mundipharma’s neuralgia/fibromyalgia pain in the seven major pharmaceutical markets, 2008 OxyContin CR, while the highly fragmented non–narcotic segment is led by BMS’ Efferalgan and J&J’s Tylenol. “Prevalence varies across these two conditions in the seven major markets, with Italy featuring the highest rate at 3.4% in 2008. Across these countries, the Pfizer was the leading player in the pain average prevalence rate of neuralgia/fibromyalgia was management market in 2007 with sales of $5.5bn, 2.2% in 2008, with the 5EU market accounting for a 14.6% increase over 2006. Celebrex registered sales of 45.6% of sufferers...” $2.3bn, followed by Lyrica with $1.9bn. Together these brands accounted for 75.5% of Pfizer’s overall sales in 2007. Orexo AB's and Prostraken’s Rapinyl/Abstra and King's and Durect’s Eladur are the most promising advanced formulations to recently enter Phase III trials. Rapinyl/Abstral is intended for breakthrough cancer pain and Eladur is the first bupivacaine formulation to receive orphan status from the FDA. Use this report to... • Assess patient potential, treatment trends • Compare the market performance and and sales patterns of major pain indications strategic positioning of major pharma over the period 2008-14, with this report’s companies’ pain management portfolios as of coverage of neuropathic and nociceptive pain H1 2008 with this report’s evaluation of the sub-categories across Japan, France, franchises of Pfizer, J&J, Novartis, GSK Germany, Italy, Spain, the UK and the US. Mundipharma, Abbott, Sanofi-Aventis, UCB, Teva and Endo Pharma. • Understand the market dynamics of the global pain management market with this • Forecast sales for key currently marketed report’s analysis of major drug classes and pain management therapies as well as regional trends, and understand the impact of leading pipeline products over the period recent events by assessing key market issues 2008–14, assess the latest trends influencing and growth drivers. R&D and evaluate leading developmental products and new chemical entities.
  • 4. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Explore issues including... M&A activity fuels market growth. Several in/out–licensing deals have occurred recently between major drug firms and specialty pharma companies. There have also been deals between pharmaceuticals and drug delivery specialists. Generic presence rising. Despite a lack of patent protected brands with sizeable commercial prospects, generic penetration is significant in the global pain management market. There are also a large number of advanced formulations which do not command Table 5.63: J&J’s leading pain management premium pricing. products, 2006–07 “Despite high levels of sales generation by J&J’s Reduced R&D expenditure. There is an emerging blockbuster brands, Topamax and Duragesic, the chief trend focused upon line extensions and expanded drivers for the company during 2007 were its formulations. This has enticed specialty pharma and drug acetaminophen brands, led by Tylenol and its variants, delivery companies, who focus on the development of and tramadol brands, led by Ultram extended release (ER). ” novel dosage forms of existing patent expired products and niche therapies. Market entry of biologics. The use of biologics in pain management will significantly change the landscape of the market in the future, due to existing pain therapies carrying considerable side-effect profiles. Pfizer is developing the first ever biologic to be used in pain management, tanezumab, a monoclonal antibody that delivers targeted action. Discover... • What will be the major growth indications in • Which companies are best positioned to the pain management market over 2009–14? succeed in the pain management market over 2009–14? • What are the current trends within the major therapy areas of neuropathic and nociceptive • What is the forecast market size and growth pain across the seven major markets? rate over the period 2009–14 across the pain management market? • What are the most promising compounds currently in clinical development for major pain • What are the significant market and pipeline indications? developments that may shape the corporate strategies of leading companies? • What is the forecast commercial potential of these products through to 2014?
  • 5. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Sample Information Chapter 3: Global Market Analysis Competitive analysis: Tylenol and Efferalgan BMS's Efferalgan and J&J’s Tylenol continued to dominate the severely fragmented non-narcotic analgesic market, a fact attributable primarily to effective marketing strategies and brand loyalty. These brands held a standout lead in the market with a substantial share of 10.8% globally. As with other leading brands, the US contributed the majority of Tylenol’s global sales (62.1%). Efferalgan, on the other hand, is not marketed in the US and derived its sales primarily from the top five EU markets (71.5%). France was the major sales generating market for Efferalgan, contributing to 43.2% of the brand’s global sales. Efferalgan holds a distinct advantage over Tylenol with its Table 3.29: Competitive analysis of Tylenol and Efferalgan immediate onset effervescent tablets. On the other hand, Tylenol is more differentiated, considering the diverse spectrum of formulations available. Interestingly, these brands have continued to demonstrate great success in the market, despite involving acetaminophen, which lacks patent protection. The growth of the brand is attributed Business Insights to the variety of formulations available and due to a successful marketing practice. Acetaminophen is indicated in the treatment of mild pain, particularly in the first- line treatment of mild nociceptive pain. Efferalgan, with 17.8% y-o-y growth, garnered $604m sales in 2007. Tylenol, with sales of $509m in 2007, demonstrated a y-o-y growth of 11.1%. In contrast to NSAIDs, acetaminophen does not have anti-inflammatory properties and is therefore not associated with producing gastrointestinal problems. Acetaminophen is also tolerable in patients with kidney disease, whereas NSAIDs can cause acute renal failure. This positive clinical profile has been at the core of J&J’s competitive marketing strategy for Tylenol: acquiring an expanded patient population that includes those who have experienced gastrointestinal problems with the use of traditional NSAIDs. Acetaminophen, however, can cause liver damage in an overdose or following consumption for long periods, particularly in conjunction with alcohol. To expand on its OTC franchise, J&J partnered with major Japanese pharma company Takeda in 2000 to launch several Tylenol products. Japan, as one of the largest OTC markets, has been crucial in positioning Tylenol as the leading acetaminophen product within the global pain market. Tylenol will continue to face strong competition from aspirin, ibuprofen, naproxen and other OTC analgesics, with Tylenol’s leading sales performance largely determined by the marketing efforts of J&J.
  • 6. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Table of Contents CHAPTER 1: SCOPE AND • Trends in generics usage and - Non-steroidal plain anti- METHODOLOGY licensing rheumatics sales forecasts to • Scope • Market analysis by drug class 2013 • Methodology • Leading brands dynamics • Topical anti-rheumatics • Key events in the autoimmune - Competitive dynamics of CHAPTER 2: EPIDEMIOLOGY OF market topical anti-rheumatics AUTOIMMUNE DISEASES - Enbrel growth slowing as it - Leading brands of topical • Introduction faces stiff competition from anti-rheumatics • Osteoarthritis Humira - Topical anti-rheumatic sales - Overview - RoActemra receives positive forecasts to 2013 - Diagnosis, treatment and opinion in Europe for the • Coxibs management treatment of RA - Competitive dynamics of - Epidemiology - NICE admits previous coxibs - Forecast epidemiology guidance around sequential - Leading brands of coxibs • Rheumatoid arthritis use of anti-TNF therapies in - Key brands analysis - Overview RA is unfair - Coxibs sales forecasts to 2013 - Diagnosis, treatment and - Study shows prohibitive cost of • Non-steroidal (combinational) management MS treatment anti-rheumatics - Epidemiology - Mayo Clinic collaborates to - Competitive dynamics of - Forecast epidemiology advance Crohn's treatment non- steroidal (combinational) • Crohn’s disease - Arthritis research shows better anti-rheumatics - Overview disease management is more - Leading brands of - Diagnosis, treatment and important than the use of non-steroidal (combinational) management drugs anti-rheumatics - Epidemiology - CellCept’s off-label use in - Non-steroidal (combinational) - Forecast epidemiology lupus continues to increase anti-rheumatics sales forecasts • Systemic lupus erythematosus • Immunosuppressants to 2013 - Overview - Competitive dynamics of • Anti-rheumatic corticosteroids - Diagnosis, treatment and immunosuppressants - Competitive dynamics of anti- management - Leading brands of rheumatic corticosteroids - Epidemiology immunosuppressants - Leading brands of - Forecast epidemiology - Key brands analysis anti-rheumatic corticosteroids • Ulcerative colitis - Clinical developments - Anti-rheumatic corticosteroids - Overview - Immunosuppressants sales sales forecasts to 2013 - Diagnosis, treatment and forecasts to 2013 • Total autoimmune sales forecasts management • Specific anti-rheumatic agents to 2013 - Epidemiology - Competitive dynamics of - Forecast epidemiology specific anti-rheumatic agents CHAPTER 4: PIPELINE ANALYSIS • Multiple sclerosis - Leading brands of specific anti- • Introduction - Overview rheumatic agents • Key trends in R&D - Diagnosis, treatment and - Key brands analysis - Biologics management - Specific anti-rheumatic agents - Combination drugs - Epidemiology sales forecasts to 2013 - Forecast epidemiology • Non-steroidal plain - Aggressive medical therapy anti-rheumatics becoming the standard of care CHAPTER 3: GLOBAL MARKET - Competitive dynamics of non- - TNF inhibitors has a strong ANALYSIS steroidal plain anti-rheumatics presence in autoimmune • Summary - Leading brands of non- market • Introduction steroidal plain anti-rheumatics - Efforts to develop fully human • Market analysis by country - Key brands analysis monoclonal antibodies
  • 7. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Table of Contents • The autoimmune pipeline - Drivers of growth - Resistors of growth • Leading drugs in development - Resistors of growth • Astellas • Profiles of key pipeline products • Abbott - Overview - Phase III compounds - Overview - Sales focus by drug class - Licofelone (ML3000) – Merckle - Sales focus by drug class - Marketed product portfolio GmbH - Marketed product portfolio - R&D pipeline analysis - Ocrelizumab (R-1594) – - R&D pipeline analysis - Strategic and growth analysis Genentech, Biogen IDEC, - Strategic and growth analysis - Drivers of growth Chugai and Roche - Drivers of growth - Resistors of growth - LymphoStat-B (belimumab) – - Resistors of growth Human Genome Sciences • Johnson and Johnson LIST OF FIGURES (HGS) and GSK - Overview • Worldwide autoimmune market - Ofatumumab (HuMax-CD20) – - Sales focus by drug class share by geography, 2007 Genmab and GSK - Marketed product portfolio • Sales of types of autoimmune - Fingolimod (FTY-720) – - R&D pipeline analysis brands, 2007 Novartis/Mitsubishi Tanabe - Strategic and growth analysis • Prevailing treatment approach for Pharma - Drivers of growth arthritis (OA and RA) - Fampridine-SR – Acorda - Resistors of growth • The autoimmune pipeline by - Campath (alemtuzumab) – • Pfizer indication and stage of Genzyme and Bayer Schering - Overview development, 2007 Pharma - Sales focus by drug class • Leading recently launched - Recently approved/marketed - Marketed product portfolio products and late-stage R&D in drugs - R&D pipeline analysis the autoimmune disorders - Cimzia (certolizumab pegol) – - Strategic and growth analysis market, 2008 UCB - Drivers of growth • Competitive dynamics of the - Golimumab (CNTO-148) – - Resistors of growth leading players in the global Centocor/Schering-Plough • Novartis autoimmune market, 2007 - Actemra (tocilizumab) – - Overview • Amgen’s autoimmune sales by Roche/Chugai - Sales focus by drug class drug class, 2007 - Tysabri (natalizumab) – - Marketed product portfolio • Abbott’s autoimmune sales by Elan/Biogen Idec - R&D pipeline analysis drug class, 2007 - Mesavance (mesalamine) – - Strategic and growth analysis • J&J’s autoimmune sales by drug Shire - Drivers of growth class, 2007 • Pipeline forecasts - Resistors of growth • Pfizer’s autoimmune sales by - Factors affecting forecasts • Wyeth drug class, 2007 - Autoimmune pipeline forecast - Overview • Novartis’ autoimmune sales by - Wyeth and Pfizer drug class, 2007 CHAPTER 5: COMPETITIVE - Sales focus by drug class • Wyeth’s autoimmune sales by LANDSCAPE - Marketed product portfolio drug class, 2007 • Introduction - R&D pipeline analysis • Roche’s autoimmune sales by - Sales performance of leading - Strategic and growth analysis drug class, 2007 players - Drivers of growth • Astellas autoimmune sales by • Detailed analysis of leading - Resistors of growth drug class, 2007 autoimmune players • Roche • Amgen - Overview LIST OF TABLES - Overview - Sales focus by drug class • Estimated prevalence of - Sales focus by drug class - Marketed product portfolio autoimmune diseases across - Marketed product portfolio - R&D pipeline analysis seven major markets, 2007 - R&D pipeline analysis - Strategic and growth analysis • Estimated prevalence of OA - Strategic and growth analysis - Drivers of growth across seven major markets,
  • 8. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Table of Contents 2007 • Leading specific anti-rheumatic • Autoimmune pipeline sales • Forecast epidemiology of OA brands in the global autoimmune forecasts, 2007–13 across seven major markets, market, 2006–07 • Leading players in the global 2007–13 • Enbrel launch status in major autoimmune market, 2007–13 • Estimated prevalence of RA markets ($m) across seven major markets, • Specific anti-rheumatic agents • Amgen’s autoimmune product 2007 sales forecast, 2007–13 portfolio, 2006–07 • Forecast epidemiology of RA • Leading non-steroidal plain anti- • Amgen’s autoimmune R&D across seven major markets, rheumatic brands in the global product pipeline, 2008 2007–13 autoimmune market, 2006–07 • Abbott’s autoimmune product • Estimated prevalence of CD • Non-steroidal plain anti- portfolio, 2006–07 across seven major markets, rheumatics sales forecast, • Abbott’s autoimmune R&D 2007 2007–13 product pipeline, 2008 • Forecast epidemiology of CD • Leading topical anti-rheumatic • J&J’s autoimmune product across seven major markets, brands in the global autoimmune portfolio, 2006–07 2007–13 market, 2006–07 • J&J’s autoimmune R&D product • Estimated prevalence of lupus • Topical anti-rheumatic sales pipeline, 2008 across seven major markets, forecast, 2007–13 • Pfizer’s autoimmune product 2007 • Leading coxib brands in the portfolio, 2006–07 • Forecast epidemiology of lupus global autoimmune market, • Pfizer’s autoimmune R&D product across seven major markets, 2006–07 pipeline, 2008 2007–13 • Coxibs sales forecast, 2007–13 • Novartis’ autoimmune product • Estimated prevalence of UC • Leading non-steroidal portfolio, 2006–07 across seven major markets, (combinational) anti-rheumatic • Novartis’ autoimmune R&D 2007 brands in the global autoimmune product pipeline, 2008 • Forecast epidemiology of UC market, 2006–07 • Wyeth’s autoimmune product across seven major markets, • Non-steroidal (combinational) portfolio, 2006–07 2007–13 anti-rheumatics sales forecast, • Wyeth’s autoimmune R&D • Estimated prevalence of MS 2007–13 product pipeline, 2008 across seven major markets, • Leading anti-rheumatic • Roche’s autoimmune product 2007 corticosteroid brands in the portfolio, 2006–07 • Forecast epidemiology of MS global autoimmune market, • Roche’s autoimmune R&D across seven major markets, 2006–07 product pipeline, 2008 2007–13 • Anti-rheumatic corticosteroids • Astellas’s autoimmune product • Worldwide autoimmune sales by sales forecast, 2007–13 portfolio, 2006–07 countries, 2007 • Therapeutic sales forecasts by • Astellas’s autoimmune R&D • Breakdown of the global drug class, 2007–13 product pipeline, 2008 autoimmune market by drug • An overview of Licofelone class, 2007 • An overview of Ocrelizumab • Leading brands in the global • An overview of LymphoStat-B autoimmune market, 2007 • An overview of Ofatumumab • Leading immunosuppressant • An overview of FTY-720 brands in the global autoimmune • An overview of Fampridine-SR market, 2006–07 • Fampridine-SR Phase III data • Remicade launch status in major • An overview of Campath markets • An overview of Cimzia • Immunosuppressants sales • An overview of Golimumab forecast, 2007–13 • An overview of Actemra • An overview of Tysabri • An overview of Mesavance
  • 9. The Pain Management Market Outlook to 2014 Competitive landscape, pipeline analysis and growth opportunities Go interactive! Competitive dynamics of leading brands in Full portfolio searchability the global cancer market, 2005-06 Search across the full structure and text of reports using i-Reports fast and powerful search tool to find the exact report “Schizophrenia and depression treatments are sections you need with ease. Presentation ready tables and graphics Create bespoke presentations using i-Reports advanced tools to collate and organize content. Just select and drag the tables and graphics directly into your own documents. Create your own report Build a report based upon your own criteria by using the i-Report keyword search facility and select only the report sections that are relevant to your project. Translate into nine major languages View any report with a ‘side-by-side’ translation in the following languages: • French • German • Italian Use our unique interactive facility to gain even more from our reports. • Portuguese • Spanish • Russian See the order form for purchase details. • Chinese • Japanese • Korean Related titles... The Autoimmune Market The Cancer Market Innovations in The Management Outlook to 2013 Outlook to 2013 of Diabetes Review the underlying trends that are Discover the key market trends and Understand the latest innovations in shaping the market and forecast the growth drivers of the cancer market, diabetes treatments, assess the potential for currently marketed and assess leading pharma companies currently marketed portfolios and key pipeline products over the and evaluate the future prospects of pipelines of leading players and 2009-13 period. major products with this report. identify future market opportunities. Published: April 2009 Published: December 2008 Published: June 2008 Price: £1995/ 2880/$3835 Price: £1995/ 2880/$3835 Price: £1995/ 2880/$3835 For further information on any of the above titles, please e-mail marketing@globalbusinessinsights.com
  • 10. FAX BACK TO: +44 (0) 207 900 6688 or scan and e-mail to marketing@globalbusinessinsights.com I would like to order the following report... 1 Company details 3 (Please use BLOCK CAPITALS) Company name: ________________________________________________________ ______________________________________________________ EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number: ______________________________________________________ _____________________________________________________________________________________________ Hard Copy (extra £50/€75/$95) Interactivity (extra £50/€75/$95) Please allow 28 days for delivery Search, customize & translate content Purchase Order Number (if required)_____________________________________ Please select a license type: 2 Payment method 4 GB£ EUR US$ Please indicate your preferred currency: GB£ EUR US$ Single User 1995 2880 3835 (eCopy) Total order value is ____________________________ Access permitted for one individual only I will forward a check payable to Business Insights Limited. Site Please invoice my company (please complete invoice address below) 3790 5470 7285 License I would like to pay by bank transfer (email address required) Access permitted for every individual based at one location Debit my credit/charge card: Amex Visa Mastercard Company 7475 9180 12180 Card No________________________________________________________________________ License Global access for every individual member of staff at the company Expiry Date _________ / _________ Signature ______________________________ To ask a question about license types, email: marketing@globalbusinessinsights.com Communications Feedback Payor details 5 Please let us know if any of the following factors influenced your purchase... Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS) Email/Fax/Postal promotion Trade Press Brochure My Account Manager First Name: Last Name: Table of Contents Conference materials Colleague Recommendation Website/web search Email Job Title Recipient details (If different from Payor) Department Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS) Address First Name: Last Name: Email City State/Province Job Title Country Post Code/ZIP Department Tel Address Fax City State/Province Sign here to confirm your order: Country Post Code/ZIP Tel Fax ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

×